The psychedelic renaissance will resemble the 1960s, only this time, it will take place under medical authorities and state supervision, with the corporate sheen of celebrity endorsement.
We can no longer avoid questions about the elevation of Remdesivir and suppression of hydroxychloroquine.
Loans to Kodak will allow the United States to produce 25 percent of the ingredients needed for pharmaceutical production.
The ‘trade benefits all countries’ school of thought that has championed trade with China is essentially flawed, since it is based on short-run considerations.
The FDA’s failures are a result of too much regulatory dithering and bureaucracy. Yet the Times’ prescriptions for change would just increase the dose.
American consumers deserve fair prices for our excellent health care. But lawmakers won’t deliver those prices by trying to control the market.
Many innovative, low-tech approaches to medicine help patients and help reduce the frequency of hospitalizations and, therefore, health care costs.
Chris Jacobs joins the Federalist Radio Hour to discuss his new book, “The Case Against Single Payer: How ‘Medicare for All’ Will Wreck America’s Health Care System.”
In the United States, antimicrobial resistance causes more than 2 million infections and 23,000 deaths per year—the equivalent of a Boeing 747 crashing each week.
As much as transgender ideologues disguised as doctors want to claim otherwise, some drugs pose serious and lasting risks to children.
If the ‘purpose of this regulation’ is to affect pharmaceutical pricing, then confining disclosures only to television advertisements would by definition have a limited impact.
Very few lawsuits against opioid makers were brought by victims or their families. Instead, they are being filed by cities, state’s attorneys general, and even Native American tribal councils.
The administration proposes changing the FDA’s name to the ‘Federal Drug Administration,’ making clear that its focus will solely be on drugs, devices, biologics, and tobacco.
While such costs represent a small fraction of overall spending on health care, several dynamics help the prescription drug issue gain disproportionate attention.
A Congressional Budget Office (CBO) document released quietly on Thursday hinted at a major gaffe by the budget agency and its efforts to conceal that gaffe.
Here’s a solution: stop focusing on trying to control prescription drug prices, and start paying attention to who’s paying them.
Reason Reporter Mike Riggs joins Federalist Radio to share the latest news and drug policy we are seeing from the new FDA commissioner.
A major anti-addiction nonprofit organization is getting big bucks from the pharmaceutical industry. Whose interests are the American Society of Addiction Medicine serving?
- The Media Didn’t ‘Get It Wrong’ On Lafayette Park, They Lied To America — And They’re Still LyingOn June 1, 2020 and afterward, corporate media didn't scontinue reading >
- Too Fat To Fly: FAA Updates Guidelines As American Obesity Crisis GrowsThe consequences of excessive weight gain have moved frcontinue reading >
- Biden’s Climate Change Stance Exposes A Delusional AdministrationIt's no wonder Biden joked to the troops, 'I keep forgecontinue reading >